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Abstract
Characterization of Deiodinase Expression in the Hypothyroid Developing Cochlea
Maria A. Uscategui Calderon
Master of Science in Biology
Minnesota State University, Mankato
Mankato, Minnesota, 2020
Thyroid hormone (TH) is essential for cochlear development and normal auditory function.
Considering the importance of TH in mediating cochlear development, understanding the
degree to which developing tissues can adapt to perturbations in thyroid hormone signaling
is extremely important. The deiodinases (D2 and D3) are enzymes that tightly control TH
availability at the tissue level and have been proposed to function as adaptive mechanisms
that maintain tissue TH homeostasis. D2 converts thyroxine (T4) to a biologically active
ligand triiodothyronine (T3); locally amplifying a T3 signal. Conversely, Dio3 inactivates
T3 and T4 by converting these iodothyronines to the inactive metabolites diiodothyronine
(T2) and reverse T3 (rT3), respectively. During cochlear development, Dio3 expression is
high prenatally while Dio2 expression is low. During the first postnatal week, the
expression levels of these enzymes invert, resulting in high expression of Dio2 and low
expression of Dio3. Together, the deiodinases control the timing of postnatal cochlear
remodeling; suggesting a genetic developmental clock controls TH-mediated cochlear
development.
Considering the role deiodinases have as an adaptive mechanism, it is important to
understand whether such a developmental clock can be negated during times of
developmental thyroid hormone insufficiency. We hypothesize that the perinatal change in
deiodinase expression is controlled by a developmental clock rather than environmental
clues and therefore have limited capacity to function as compensatory mechanisms in
response to low TH during development. To test this, timed-pregnant mice were treated
with thyroid gland inhibitors to induced hypothyroidism from gestational day 12.5 until
pup sacrifice. A parallel set of untreated timed-pregnant mice served as controls. Cochlea
were harvest from control and hypothyroid mice at postnatal ages P1, P5, P10 and P15 for
qRT-PCR. We observed D2 and D3 mRNA levels were similar or reduced in hypothyroid
animals compared to controls at P1, P5, and P10. This finding indicates that at these ages,
D2 at did not respond in a manner consistent with the idea of compensation. However, at
P15, D2 mRNA levels were increased in hypothyroid animals compared to controls; a
finding that is consistent with a compensatory mechanism. Interestingly, decreased D3
mRNA levels observed in the hypothyroid cochlea is indicative of an adaptive response
that could be attempting to compensate for the goitrogen-induced reductions in T4. Taken
together, our results suggest that developmental programs in tissues may be dominant over
potential compensatory mechanisms and that developing tissues may be more susceptible
to perturbations in tissue TH levels due to a reduced capacity to compensate.
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Introduction
Thyroid hormone is essential for proper development of the nervous and sensory
systems (Sharlin 2015). Particularly, development of the cochlea requires active thyroid
hormone (triiodothyronine; T3) for cochlear differentiation and ultimately proper auditory
system function. Thyroid hormone must be available during critical developmental
windows prior to the onset of auditory function because at later stages auditory deficits
cannot be reversed by thyroid hormone supplementation ( Ng et al. 2004; Sharlin 2016).

Deiodination reactions carried out by Type 2 deiodinase (D2)

and Type 3

deiodinase (D3) regulate thyroid hormone signaling at the tissue level due to their
activating and deactivating properties, respectively (Williams and Bassett 2011). In many
developing tissues, including the cochlea, pre- and perinatally D3 activity is high where as
D2 activity levels are low. Postally, the activity pattern inverts, with D3 levels low and D2
levels high. This pattern is known as the “double switch” and is required to trigger
remodeling of cochlear tissues and timing for the onset of auditory function. Previous
research has demonstrated that in the absence of D2-mediated amplification of a T3 signal
during the early postnatal period (resulting in a local tissue hypothyroidism), development
events of the cochlea are delayed that results in the improper formation of critical structures
for the onset of hearing ( Ng et al. 2017, 2009).

Based on these observations, we hypothesize that the perinatal changes in
deiodinase expression in a hypothyroid individual will follow the delayed onset of
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important remodeling events in the cochlea because this switch is controlled by a
developmental clock rather than environmental clues and therefore have limited capacity
to function as compensatory mechanisms in response to low TH during development.
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Literature review

HPT Axis
The synthesis and secretion of thyroid hormone, and thus circulating levels, is
mainly regulated through negative feedback of the hypothalamus-pituitary-thyroid axis
(HPT axis). The hypothalamus communicates through thyrotropin releasing hormone
(TRH) neurons that originate in the paraventricular nucleus. (Sharlin 2015; Ng et al. 2013;
Santisteban 2013). These neurons release TRH to the anterior pituitary and stimulate
thyrotrope cells to secrete thyroid stimulating hormone (TSH) into the bloodstream. TSH
regulates the activity of the thyroid gland, which secretes thyroxine (T4) and
triiodothyronine (T3) directly into the bloodstream. The thyroid gland secretes higher
amounts of the prohormone T4 than the active form T3. T4 is converted into the
biologically active form T3 locally in tissues by extrathyroidal deiodination enzymes;
providing a mechanism to regulate TH action directly in a tissue.
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Figure 1. Overview of the deiodination process of thyroxine (T4) into Triiodothyronine
(T3) by Type Ⅱ deiodinase enzyme or Reverse T3 (rT3) by type Ⅲ deiodinase enzyme.
Picture taken from Bianco et al, 2011.

Deiodinases
Iodothyronine deiodinases are peroxidase enzymes that regulate the local extra- and
intracellular concentrations of thyroid hormone thereby regulating thyroid hormone action
at receptors (Williams and Bassett 2011). As mentioned above, thyroid hormone is secreted
into the blood stream as T3 and T4, with T4 secretion being 10 times greater than T3. T4
must be converted to T3 by deiodination of an iodine from the outer phenolic ring to yield
the biologically active T3 (Bianco and Kim 2013). The deiodination reaction is carried out
by three different types of deiodinases. Type 1 deiodinase can catalyze both the activating
and inactivating reactions. This type is mainly found in the liver and is proposed to be
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important in metabolizing thyroid hormone for excretion. D2 catalyze the activating
reaction; while D3 has a role in the inactivation of both T3 and T4 (Fig. 1). In the cochlea,
Type 1 is not present. However, important roles for D2 and D3 enzymes have been
reported (Ng et al. 2017, 2009).
The expression of both D2 and D3 enzymes is regulated in a tissue- and timespecific manners, which as a result controls the varying levels of T3 action at different
times during development. In the developing cochlea, D3 is high during embryonic and
perinatal timepoints when D2 levels are low. This high level of D3 in tissues T3 action at
the receptor. Postnatally, the expression pattern inverts; with D3 decreasing to low levels
during the first postnatal week while there is a simultaneous and robust increase in D2
levels until about postnatal day 10 at which times D2 levels begin to fall to adult levels.
Such developmental and robust changes in deiodinase are likely due to histone
modifications known to mediate changes in gene expression by modifying the chromatin
structure and freeing compact chromatin into an accessible form for transcription factors
to bind, enhancing gene expression (Ambrosio et al. 2013). This idea is supported by the
findings that in muscle histone H3 demethylating enzyme (LSD-1) is necessary for
induction of D2 transcription and repression of D3 in muscle pre-cursor cells. (Ambrosio
et al. 2013). It is unknown whether similar histone modifying mechanisms operate in the
developing cochlea.
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Thyroid hormone receptors
Encoded by two independent genes, thra and thrb, thyroid hormone receptors (TR)
serve as ligand-regulated transcription factors that mediate specific actions of T3 (Ng et
al.2013). Alternative splicing of the thra and thrb genes generates receptor subtypes TRα1,
TRβ1, TRα2 and TRβ2 (Jones et al. 2003). All four isoforms are expressed in the cochlea
(Bradley et al. 1992). TRα1, TRβ1, and TRβ2 are bona fide receptors that bind T3. In
contrast, the TRα2 isoform lacks a ligand binding domain and thus can bind DNA, but
since it is unable to bind ligand, it is unable mediate ligand-dependent TH action.

In the cochlea, TRα transcripts are mostly found prenatally in the sensory
epithelium, spiral ganglion and the vestibular system, suggesting that these regions are
sensitive to circulating T3 levels before birth and any disruptions may potentially lead to
pathophysiological changes (Lautermann and Ten Cate 1997). However, mice lacking
TRα do not show auditory impairment (Rusch et al. 2001). TRα2 has been found to be
expressed in the same regions as TRα1 in the cochlea ( Sharlin 2016; Bradley et al. 1992).

Additional knockout studies demonstrated TRβ is essential for cochlear
development and auditory function (Rusch et al. 2001; Ng et al. 2001). TRβ1 and TRβ2
are expressed in several cochlear regions, including the greater epithelial ridge (GER) and
sensory epithelium. TRβ expression overlaps TRα in the GER and sensory epithelium.
TRα1 is expressed at lower levels than TRβ1 and TRβ2 (Cordas et al. 2012). Interestingly,
the TRβ knockout mice are deaf (Rusch et al. 2001; Lily Ng et al. 2001; Griffith et al. 2002)
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while the TRα knockout mouse has normal hearing abilities (Rusch et al. 2001; Ng et al.
2001). Double knockouts of both TRβ and TRα exhibit aggravated deficits in hearing when
compared to the single knockouts of TRβ. This difference in hearing deficits suggests that
TRα is highly involved in the development of hearing (Richter et al. 2011; Winter et al.
2007; David J. Bradley, Towle, and Young 1994; Rusch et al. 2001).

Thyroid hormone in Cochlear development
Physical and mental disabilities have been observed in individuals with congenital
thyroid hormone disorders such as congenital hypothyroidism or resistance to thyroid
hormone due to mutations in the receptor genes (Rusch et al. 2001; Sharlin 2015; Peeters
et al. 2015). These observations highlight the importance of thyroid hormone signaling
during specific developmental stages of the nervous system. In particular, deafness caused
by improper development of the cochlea, the auditory sensory organ, has been identified
as a TH target tissue in developmental thyroid hormone insufficiency in both humans and
rodent models (Ng et al. 2017).

Experimental studies have demonstrated that cochlear development is sensitive to
T3 towards the end stages of cochlear differentiation. In humans, this period occurs
between 9 and 18 weeks of gestation (Locher et al. 2015). In rodents, the overall structure
of the cochlea is formed before birth but continues to remodel until around 2 weeks of age
(Peeters et al. 2015). Specifically, T3 influences the remodeling of the GER, a transient
structure that regresses during the first two postnatal weeks. This mass of cells gives way
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to the inner sulcus and secretes the proteins that will form the acellular tectorial membrane,
a critical structure for auditory function ( Sharlin 2016; Peeters et al. 2015).

Additionally, hypothyroid models have shown that decreased exposure to T3
during development causes a delay in important physiological functions in inner and outer
hair cells. Additionally, insufficient TH has also be reported to delay the remodeling GER
and inner sulcus epithelium. This disruption results in improper suspension of the tectorial
membrane, as well as improper expression of membrane glycoproteins α and β-tectorin.
This observation provides a possible explanation for the swelling and disorganized
microstructure of the tectorial membrane observed in hypothyroid cochlea (Knipper et al.
2001). Similarly, experiments in mice lacking thyroid hormone receptors have defined an
essential role for TRβ in GER regression and tectorial membrane formation (Rusch et al.
2001).

Fewer studies have examined the effects of hyperthyroidism on cochlear
development, but the general observation is that effect is opposite to the effects observed
in hypothyroid models. Ng et al. (2009) injected excessive T3 into neonatal mice and
measured their auditory function 28 days after injections. This study tested the auditory
evoked brainstem response (ABR) and the distortion product otoacoustic emission
(DPOAE) which showed that excessive exposure to T3 caused severe auditory deficits (Ng
et al. 2009).
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Role of Deiodinases in Cochlear Development
D2 is expressed in the connective tissue surrounding the sensory epithelium and its
activity peaks 7 days after birth (P7). D2 has an essential role in the availability of active
thyroid hormone in the developing cochlear tissue and therefore is necessary for the proper
formation of the cochlea and normal auditory function (Williams and Bassett 2011). In the
D2 knockout mouse, GER remodeling is delayed and auditory function is deficient, similar
to deficiencies found in individuals with complete absence of receptors as well as those
with severe hypothyroidism (Ng et al. 2004; 2009). These phenotypic findings highlight
the importance of proper D2 expression during the developmental stages.

Just as crucial, D3 plays a role in the proper development of the cochlea. D3
diminishes the actions of T3 and T4 in the tissue by producing biologically inactive reverse
T3 (rT3) or diiodothyronine (T2). Studies with D3 knockout mice showed that the primary
role of this enzyme is to protect the GER from premature exposure to thyroid hormone. In
its absence, there is early differentiation of the GER which leads to poor auditory function
(Ng et al. 2009). The same study also showed that the expression of this enzyme is, for the
most part, limited to the GER and the stria vascularis.

Adaptive mechanism to maintain normal tissue TH action
The HPT controls circulating levels of thyroid hormone within a relatively narrow
range. Hypothyroidism (under-active thyroid gland) is a thyroid condition characterized by
low circulating thyroid hormone levels in the blood. Hyperthyroidism (over-active thyroid
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gland), is a condition characterized by excess thyroid hormone in circulation. Having either
of these disorders can be unfavorable, especially for an organism with developing tissues.
It is proposed that developing and mature tissues possess adaptive mechanisms that aim to
normalize tissue thyroid hormone levels in situations where disorders in serum thyroid
hormone occur (Sharlin et al. 2010). One specific adaptive mechanism is the deiodinases,
which may protect developing tissues due to their ability to activate or inactivate thyroid
hormone locally. Therefore, the direct availability of this hormone is dependent on the
upregulation or repression of these enzymes at a tissue-specific level. For example, D2 is
sharply upregulated during myoblast differentiation whereas D3 is downregulated
(Ambrosio et al. 2013). Particularly in the cochlea, studies in both D2 and D3 knockout
mice have demonstrated the importance of deiodinases in the proper timing of thyroid
hormone action in the developing cochlear tissue (Ng et al. 2009, 2017).

From the above information it can be concluded that development of the cochlea
and normal auditory function requires a tightly controlled and regulated by a time
dependent availability of T3. This is achieved by synchronized and developmentally
inverted expression and activity of D2 and D3. Prenatal D3 activity is maintained at high
levels, with low D2 activity levels. Later, after birth, the activity pattern of these enzymes
changes, with increasing D2 activity as D3 activity is reduced, allowing T3 to trigger
remodeling of the tissues and the onset of auditory function. However, it is unknown
whether the expression of these enzymes change in response to altered thyroid hormone
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levels in a manner that would be consistent to these enzymes functioning as adaptive
mechanisms aimed at preventing tissue malformation.

The tissue activities of D2 and D3 change in response to changes in circulating TH.
During a hypothyroid state, studies have demonstrated an increased expression of D2 in
the brain (Guadaño-Ferraz et al. 1999), which could represent a compensatory response to
the low levels of T3 because increased D2 activity will increase the conversion rate of T4
to T3 to provide adequate support to the T3. However, whether the same increase in D2
happens in the T3 responsive cochlear tissues is still unknown. Simultaneously, D3 activity
decreases in the hypothyroid organism which allows for a longer residency of T3 around
the tissue (Bianco and Kim 2013).

This thesis investigates whether cochlear abnormalities following developmental
hypothyroidism are amplified by a delay in the deiodinase switch due to an overall delay
in tissue maturation. We hypothesize that in hypothyroid mice, the normal postnatal
decrease in Dio3 expression and concomitant increase in Dio2 will be delayed compared
to euthyroid mice. If observed, we propose that these altered expression levels are due, in
part, to the overall delay in cochlear development know to occur with developmental
hypothyroidism. Additionally, such an observation would suggest that developmental
programs that mediate tissue development are dominant over potential adaptive
mechanisms that aim to maintain tissue TH action; preventing compensation from
occurring.

12

Materials and Methods

Animals
C57BL/6J mice from Jackson Laboratory were housed in the animal care facility in
Minnesota State University, Mankato. Mice were given LabDiet 5001 Rodent Diet chow
and water ad libitum. All procedures were approved by Minnesota State University,
Mankato’s Institutional Animal Care and Use Committee (IACUC). Breeding dams were
monitored for the presence of sperm plug daily with a positive plug considered
embryonic day 0.5 ((E)0.5).

Hypothyroid Treatment
On embryonic day (E)12.5 the drinking water of selected cages was replaced with water
containing with 0.02% methimazole (MMI; inhibits thyroid gland thyroperoxidase
activity) and 1% KClO4 (inhibits the sodium iodide symporter). Treatment was monitored
daily and replaced every 2-3 days. Treatment of pregnant dams continued through the
embryonic period and continued postnatally until all the test subjects in the cage were
sacrificed. Euthyroid animals received untreated water from the facility and used as
control.
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Sacrifice and Sample Collection
Mice were sacrificed at post-natal day (P) 1, P5, P10 and P15. At the two early ages, pups
were rapidly decapitated. At the later ages, pups were euthanized by placement in a CO2
chamber. Following euthanasia, both cochleae were dissected from each animal using a
dissecting scope. Cochleae used for qPCR were flash frozen by placing them in dry ice and
stored at -80°C until RNA purification. Cochleae used for In-situ hybridization were fixed
in 4% paraformaldehyde (PFA) in 1xPBS for 3 hours at 4°C with light rocking. Cochlea
were then washed (3x10 minutes) with 1xPBS and then placed in a 100mM
ethylenediaminetetraacetic acid (EDTA)/ 1xPBS/30% sucrose solution for 24 hours at 4°C
with light rocking. The following day, samples were embedded in optimum cutting
temperature medium (OCT; Tissue-tek), frozen on dry ice and stored at -80°C until
cryosectioning. Additionally, a tail sample was collected for sex genotyping from P1 and
P5 pups. Trunk serum was also collected following euthanasia from both the dam and pups
to later perform a T4 ELISA for verification of euthyroid or hypothyroid state. After
collection, whole blood was placed on ice for no longer than 30 mins and then centrifuged
at 12000rpm for 10 minutes. After centrifugation, serum was removed from the tube and
stored at -20°C until further use.

Cryosectioning
Mid-modiolar cochlear sections were cut at 16 µm. Sections were thaw mounted onto
Superfrost Plus/Colorfast Plus Microslides (75x25mm; Daigger) and stored at -80°C until
staining for in situ hybridization.
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SRY Genotyping
P1 and P5 tails were lysed in 500μL of tail lysis buffer (10 mM Tris, pH 8.0, 100 mM
NaCl, 10 mM EDTA, pH 8.0, 0.5 %SDS) with 20μg/mL Proteinase K. Samples were
incubated at 56°C with constant shaking at 1500rpm for 2 hrs. After lysis, samples were
centrifuged for 10 minutes at 13200rpm to remove debris and 450μL of the supernatant
was removed from each sample avoiding the pellet. Then, 450 μL of isopropanol was added
to each tube containing the supernatant. Next, the samples were mixed by inverting to allow
DNA precipitation. Precipitated DNA was transferred into 500μL of DEPC-H2O and
shaken at 1000rpm for 5 minutes at 56°C to dissolve DNA.
To detect the SRY gene by PCR, 0.2 μM forward and reverse SRY primers and 0.12μM
forward and reverse primers for IL3, nuclease free H2O, and 2x GoTaq PCR Master mix
(Promega) were mixed to a final volume of 19ul. 1μL of each DNA sample was added.
Samples were then mixed, briefly centrifuged, and placed in a thermal cycler as follows:
95°C for 4 minutes, followed by 35 cycles of 95°C for 30 seconds, 50°C for 1 minute, and
72°C for 1 minute. Then, the samples were incubated at 72°C for 6 minutes and held at
4°C. All samples were electrophorosed on a 1.5 % agarose gel with one band indicating
females and two bands indicating males (Fig. 2).
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IL3

SRY

Figure 2. SRY genotyping. All lanes show a band for control gene, IL3. Males have a second band
for male-specific gene SRY.

ELISA Assay
Concentrations of T4 in serum were measured by Enzyme-Linked Immunosorbent Assay
(ELISA) using the AccuDiag™ T4 ELISA Kit and the manufacturer’s protocol (Diagnostic
Automation/Cortez Diagnostics Incorporated).

RNA isolation and cDNA synthesis
Total RNA was isolated using the RNeasy Plus Universal Mini kit (Qiagen). The
concentration and purity of the isolated RNA was measured using a nanodrop and stored
at -80°C. RNA quality was determined by gel electrophoresis of 2 μL of each sample on a
1% agarose bleach gel. Pure samples showed two distinct bands: a larger 28S rRNA band,
a smaller 18S rRNA band and a lack of genomic DNA band contained in the gel well (Fig
3).
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28S rRNA

18S rRNA

Figure 3. Bleach gel for RNA quality. RNA was of good quality. Indicated by
the presence of two bands: 28s rRNA and 18s rRNA.

cDNA was synthesized from total RNA using the SuperScript IV VILO Master Mix
(Thermo Fisher). Samples with a concentration below 90 ng/μL used 200 ng total RNA as
a template. All other samples used 500 ng of total RNA as a template. Following cDNA
synthesis, sample reactions were diluted to a final RNA mass of 50ng/μL.

Real-Time Quantitative PCR (mRNA RT-qPCR)
Using TaqMan Gene expression Assay probes (ThermoFisher; Table 1), D2 and D3 mRNA
transcripts were quantified using a Step One Plus Real-Time PCR machine (Applied
Biosystems). The relative amounts of RNA expression were calculated using 18S rRNA as
an internal normalization control. Relative RNA amount was determined by the standard
curve method using 5-fold dilution. RNase-free water was used as a negative template
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control in the place of a cDNA template. The thermocycler program followed the TaqMan
probe protocol. The efficiency of each primer set was calculated. For the amplification, the
thermocycler program includes the following steps: initial denaturation at 95°C for 10
minutes, 40 cycles at 95°C for 15 seconds each, and an annealing/extension step at 60°C
for 1 minute

Table 1. qRT-PCR primers (Applied Biosystems)

Gene

Primer-Probe Reference Number

dio2

Mm00515664_m1

dio3

Mm00548953_s1

18S rRNA

Mm03928990_g1

In Situ Hybridization: Probe Generation
Dio3 cDNA cloning
To clone a Dio3 cDNA fragment (NM_172119.2) primers were tested to determine proper
concentration and annealing/extension temperature for optimal efficiency. Two primer sets
(Table 2) were tested (a and b) at three different concentrations (0.1 µM, 0.3 µM, 0.5 µM)
and temperatures (68 °C, 65 °C, 60 °C). Samples were diluted and placed in thermocycler
with the following protocol: 95°C for 2 minutes; 40 cycles of 95°C for 15 seconds, 6068°C for 15 seconds, 72°C for 5 minutes; infinite hold at 4°C. Samples were
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electrophorosed on a 1.5 % agarose gel. The primer selected was set A at a 0.3 µM with an
annealing temperature of 60°C because it showed a clear band without any smearing as
shown in fig. 4. This primer set amplifies base pairs 329-865 of Mus musculus Dio3 mRNA
(NM_172119.2).

Set A
0.1 µM

Set B

0.3 µM

0.5 µM

0.1 µM

0.3 µM

0.5 µM

60 OC

65 OC

60 OC

68 OC

68 OC

65 OC

65 OC

60 OC

68 OC

60 OC

65 OC

68 OC

60 OC

65 OC

68 OC

60 OC

68 OC

1000 bp

65 OC

5000 bp

500 bp

100 bp

Figure 4. Dio3 partial cDNA primer test. Primer sets A and B were tested at
concentrations 0.1 µM, 0.3 µM, 0.5 µM and temperatures 68 °C, 65 °C, 60 °C.
The primer selected was the one with the clearest band and minimal smearing:
A,0.3 µM, 60°C.

Forward Primer

5’ -CACCCTGGCCTCTCTCAAAG-3’

5’ -GTGGTCGGAGAAGGTGAAGG-3’

Primer Set

A

B

Table 2. Partial Dio3 cDNA primers.

5’ -GGTGGGCTTCCTCGATGTAG-3’

5’ -CAAGTGCGCAACTCAGACAC-3’

Reverse Primer

NM_172119.2
NM_172119.2

327-863
28-607

536 bp
579bp

Accession #

Base pairs

Amplicon size
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Ligation
Amplified fragments obtained from PCR described above was purified using GeneJET Gel
Extraction and DNA Cleanup Micro Kit protocol (Thermo Fisher). Ligation of partial Dio3
cDNA and pGEMT-Easy vector was performed using pGEM T-Easy Vector (Promega),
2x rapid ligation buffer, T4 DNA Ligase, and purified PCR product. Purified plasmids were
digested to verify that they contained the Dio3 insert (Fig. 5).

Transformation
JM109 cells were transformed with a Dio2 and Dio3 plasmids and plated on
ampicillin/IPTG/X-Gal-containing agar plates. Several single colonies were selected to
grow in culture of luria broth (LB) with ampicillin overnight.

DNA Plasmid Purification
Genejet Plasmid Miniprep kit protocol (Thermo Fisher) was used to purify the plasmid
following manufacturer instructions. Concentration of purified plasmid was determined
spectroscopically using a nanodrop and purified plasmids were stored at -20°C.

Plasmid Digest
EcoR1 enzyme (New England Biolabs) was used to verify proper insert size. The samples
were electrophoresed on agarose gel. Colony 9 was selected for sequencing. Sequencing
confirmed the proper Dio3 cDNA insert (data not shown).
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Colony 6

Colony 7

Colony 8

Colony 9

Colony 10

5000bp
1500bp
500bp
EcoR1 uncut EcoR1 uncut
t

EcoR1 uncut EcoR1 uncut EcoR1 uncut
t

t

t

Figure 5. Dio3 plasmid digest. EcoR1 restriction endonuclease was used to cut the
plasmid. The cut sample was sent for sequencing to verify the presence of Dio3 insert.
EcoR1 resulted in 600bp and 5000 bp fragments shown on the gel. Colonies 9 and 10 were
selected because they showed high concentration and fragments of appropriate lengths.

Plasmid Linearization
Deiodinase plasmid was linearized using two single-cutter enzymes to obtain sense and
anti-sense single strands (Fig. 6). For Dio2, Hind III enzyme was used to cut 0.5 µg of
plasmid to obtain the anti-sense probe and PST I enzyme (New England Biolabs) was used
to cut 0.5 µg of plasmid for a sense (negative control). For Dio3, Sac II was used to cut 0.5
µg of plasmid for anti-sense probe and PST I enzyme was used to cut 0.5 µg of plasmid
for a sense probe (Table 3). The plasmid was incubated with the restriction enzymes for 2
hours then purified using GeneJET Gel Extraction and DNA Cleanup Micro Kit protocol
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(Thermo Fisher). The concentration of the purified, linearized DNA template was
determined, and samples were electrophorosed on a gel to confirm proper linearization.

Dio2

Dio3

Antisense

Sense

Uncut

Sense

Uncut

3000bp

Antisense

5000bp

Figure 6. Dio2 and Dio3 linearized sense and antisense plasmids. Linearized plasmids obtained
by using restriction endonucleases. Linearized plasmids were approximately 4800bps

Table 3. Single-cutter enzymes used obtain sense and anti-sense
single strands (New England Biolabs)

Plasmid

Antisense Enzyme

Sense Enzyme

Dio2

HindIII

PST1

Dio3

NcoI

SalI
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In vitro Transcription of RNA Probes.
The DNA templates were transcribed using RNA polymerase enzymes: for Dio2, T3 for
anti-sense and T7 for sense. For Dio3, Sp6 for anti-sense and T7 for sense (Promega)
(Table 3; Fig. 7). The plasmid DNA templates were incubated in a 50µL reaction with 5
µL RNA polymerase, 5 µL of 5x transcription buffer (Promega), 5 µL 10 mM digoxygenin
NTP mix (Roche), 1 µL RNAse inhibitor (Promega), and nuclease free water at 37 °C for
2 hours. DNase I (Roche) was then added and incubated at 37 °C for 1hr to remove the
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Figure 7. Processing of Dio2 and Dio3 sense and antisense probes. DNA was transcribed
to yield RNA probes. RNA polymerases were used for reverse transcription (Trxn). For dio2,
T3 was used for anti-sense and T7 for sense strand. For dio3, SP6 was used for anti-sense and
T7 for sense strand. RNA was then treated with DNAseI, followed by alkaline hydrolysis and
precipitated via ethanol RNA precipitation.
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DNA template. Sample of the probes prior to and after DNAse I addition were collected
and electrophorosed on a gel to verify DNA removal.

Alkaline Hydrolysis and RNA Precipitation of RNA Probes
Na2CO3 and NaHCO3 were added to each reaction at a final concentration of 0.24M and
incubated at 60°C for 20 minutes. A sample was saved of the hydrolysis for gel analysis.
The probe RNA was precipitated with sodium acetate to a final concentration of 0.075 M.
Pre-chilled 100% ethanol was added such that it is 2.5x the volume in each tube. Samples
were placed at -80°C overnight. Samples were centrifuged at 13,000rpm for 30 minutes at
4°C, then washed with 70% ethanol, and resuspended in nuclease free water. Samples of
each probe were collected for gel analysis. Concentrations of probes were determined
spectroscopically using a nanodrop. Probes were diluted in hybridization buffer to a final
concentration of 20ng/µL and stored at -80°C.

Hybridization
Prehybridization DNA
Slides were removed from -80°C, thawed at room temperature, and washed 3x3 minutes
in 1xPBS. Slides were acetylated using 0.1M TEA (triethanolamine)/0.25% acetic
anhydride for 10 minutes followed by incubation in 0.1% Triton X-100 in 1xPBS for 30
minutes. Slides were washed 3x5 minutes in 1x PBS, then covered in hybridization buffer
without probe and allowed to prehybridize for 2-4 hours in a humidity chamber with 50%
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formamide/ 0.2xSSC soaked paper towels. All prehybridization washes and incubations
were carried out at room temperature.
Hybridization.
In situ hybridization were performed with antisense and sense Dio3 and Dio2 probes. Dio2
and Dio3 probes were diluted to 1000 ng/mL in hybridization buffer and heated at 80°C
for 5 minutes to remove secondary RNA structures, then placed on ice. Probe-hybridization
buffer mixture was added to each slide, cover slipped and allowed to hybridize overnight
at 68°C in a humidity chamber with 50% formamide/0.2X SSC (saline-sodium citrate)
soaked paper towels.

Post Hybridization
Slides were washed in pre-warmed 0.2xSSC (changing solutions after 5 minutes, then 3x15
minutes) in a 68-72°C water bath. Slides were cooled and washed in room temperature
0.2xSSC for 5 minutes. Slides were then separated by probe for all SSC washes.

Antibody and Alkaline Phosphate Detection
Slides were washed with maleic acid buffer (MB) for 10 minutes, and then incubated in
2% MBMB (10% Boehringer Mannheim blocking buffer in MB) for 1 hour. Antidigoxigenin-AP antibody (Roche) was diluted 1:2000 in 2%MBMB and added to each
slide in a humidity chamber. Slides were incubated overnight at room temperature. The
next day, slides were washed 2x30 minutes in MB, 2x30 minutes in color reaction buffer
(Tris pH 9.5, 5M NaCl, 1M MgCl2, Tween 20 in H2O) and covered in NBT/BCIP (p-
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nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate) (Roche) solution
diluted 1:50 in color reaction buffer. Slides were incubated with color substrate for 18-24
hours in a tin foil-covered humidity chamber. Slides were washed in 1xPBS for 10 minutes
and cover slipped with VectaMount AQ Aqueous Mounting Media (Vector Laboratories),
allowed to dry at room temperature overnight, and then imaged on an Olympus BX53
brightfield microscope. All photos were taken of regions in middle cochlear turns unless
otherwise stated.

Data Analysis
Two-way ANOVA was performed on RT-qPCR and ELISA to determine if there is an
effect of age and treatment and whether age and treatment interact. A Sidak post hoc test
was used to determine significant differences between individual comparisons. A twotailed unpaired students t- test was also used to determine whether there were significant
differences between sexes.
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Results
Effect of treatment on body weight
Mice treated with thyroid gland inhibitors had significantly lower body weight at
ages P5, P10 and P15 (Fig. 8A). A two-way ANOVA indicated an effect of age
(F(3,82)=343.7, p<0.0001****)
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Figure 8. Effect of treatment on body weight. (A) Body weight of both male and female pups at
different ages through cochlear development (n=24-28 per age per treatment). Hypothyroid pups showed
significantly lower weight at age P5 (****p<0.0001), P10 (*p=0.0128), P15(***p=0.0006) compared to
controls. (B) Serum T4 throughout development was measured by ELISA (Pooled P1 serum n=4, Pooled
P5 serum n=9, Individual P10 and P15 serum n=11 each) Sidak’s multiple comparisons demonstrated
significantly lower total serum T4 in control versus hypothyroid pups at ages P10 (*p= 0.0475) and P15
(****p<0.0001). (C) Dam serum T4 was assessed by ELISA (n=5 control, n=6 hypothyroid). Dam serum
was collected upon final pup sacrifice (P15 for all control and hypothyroid dam serum tested). Dams were
sacrificed when their pups were age P15. Comparison of control and hypothyroid dams was done using
an unpaired, two-tailed t test. Dams treated with thyroid gland inhibitors had significantly lower serum
T4 compared to control dams (*p=0.0297).
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interaction between the two. No differences in the body weight between female and male
pups of the same age was found (data not shown).

Total serum T4 was measured by ELISA to verify the efficacy of treatment. ELISA
indicated significantly lower serum T4 in hypothyroid P10 and P15 pups compared to
control pups (Fig. 8B). Two-way ANOVA showed a significant effect on age (F
8.653, ****p<0.0001), treatment (F
between the two (F

(3, 63)

(1, 63)

(3, 63)

=

= 26.21, ****p<0.0001), and the interaction

= 5.704, *p=0.0016). A significant reduction in T4 was not

observed at P1 or P5. Dam serum was analyzed to verify maternal hypothyroidism,
indicating subsequent hypothyroidism in offspring given that TH passes from maternal
circulation to pups through placental transfer (Stepien and Huttner 2019). As expected,
control dam serum had significantly higher T4 compared to hypothyroid dams (*p=0.0297)
(Fig. 8C).
Quantification of Dio2 mRNA in euthyroid and hypothyroid cochlea
qRT-PCR demonstrated that the expression of Dio2 mRNA levels in a euthyroid cochlea
peaked at P10, then decreased to almost the same level as P1, where it had its lowest
expression (Fig. 9). In contrast, mRNA levels in the hypothyroid cochlea were greatest at
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Figure 9. Dio2 mRNA expression during early postnatal development. (A) Male control
individuals had highest expression at P5, with a decrease through P15 (n= 6 male, per age, per
treatment). Hypothyroid male individuals had an increase of Dio2 expression at P10 to the
highest level at P15.Comparison of both groups found significantly higher Dio2 mRNA
expression in control pups at P5 (**p=0.0015) and higher expression in hypothyroid pups at
P15 (****p<0.0001). (B) Female control individuals had highest expression at P10, with a
decrease through P15 (n= 4-6 female, per age, per treatment). Hypothyroid female individuals
had a steady increase of Dio2 expression starting at P5 to the highest level at P15. Comparison
found significantly higher Dio2 mRNA expression in hypothyroid pups at P15(****p<0.0001).
(C) Control individuals had highest expression level at P10, with a decrease through P15 (n=6
male and female, per age, per treatment). Hypothyroid individuals had an increase of Dio2
expression from P5, P10 to the highest level at P15.Comparison of both groups found
significantly higher Dio2 mRNA expression in control pups at P5 (***p=0.0009) and higher
expression in hypothyroid pups at P15 (****p<0.0001).

P15. Dio2 mRNA levels were lowest at P1 in the euthyroid and hypothyroid group. Twoway ANOVA test were performed individually for males and females: Males showed an
effect on age (F (3, 35) = 24.30, p<0.0001****) and treatment (F (1, 35) = 11.29, p=0.0019**)
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as well as a significant interaction between the two (F

(3, 35)

= 30.53, p<0.0001****) ;

Females showed an effect on age (F (3, 35) = 35.61, p<0.0001****) and treatment (F (1, 35) =
17.55, p=0.0002***) as well as a significant interaction between the two (F

(3, 35)

=

33.15,p<0.0001****) (Fig. 9A,B). No differences were detected between male and female
pups within pups of the same age and treatment group. However, for simplicity, male and
female data was pooled since the data show the same trend whether sexes were pooled or
separate. Two-way ANOVA test of pooled data indicated an effect on both age
(F(3,78)=54.56, p<0.0001****) and treatment (F(1,78)=26.16, p<0.0001****), as well as a
significant interaction between the two (F(3,78)=56.47, p<0.0001****) (Fig. 9C). At P5,
Dio2 expression was significantly lower in hypothyroid pups compared to the euthyroid
controls for males and combined analysis (Fig. 9C) However, at P15, hypothyroid pups
had a significantly higher expression of Dio2 than the euthyroid control. Dio2 mRNA
levels between control and treated animals were observed at P1 or P10 (Fig. 9C).
Localization of Dio2 mRNA in the developing euthyroid and hypothyroid cochlea
In situ hybridization was performed to determine the spatial patterns of D2 mRNA at the
window where the switch in expression of D2 takes place postnatally. D2 mRNA
expression was present in the periosteal connective tissue in the modiolus, the
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Figure 10. Dio2 mRNA expression in the developing cochlea. (A) Comparison of D2 mRNA presence
in in the periosteal connective tissue in the modiolus, the lateral wall and the spiral lamina. D2 mRNA
was expressed in a higher amount in the euthyroid cochlea then the hypothyroid at P5. The opposite was
observed at P10. Both ages show delayed remodeling events including the prevalence of ger cells and
small inner sulcus. (B) Hematoxylin stain of euthyroid cochlea at Postnatal day 7. Black arrow heads,
outer hair cells (OHC). (C) P10 control D2 sense probe. Any staining in the sense is considered
background. Abbreviations: md, modiolus; sl, spiral lamina; ger, greater epithelial ridge; is, inner sulcus;
tm, tectorial membrane; stv, stria vascularis.

lateral wall and the spiral lamina. At postnatal day 5 Dio2 mRNA expression was visually
higher in the euthyroid cochlear tissues compared to hypothyroid tissues; consistent with
qRT-PCR results (Fig. 10 A). At postnatal day 10 Dio2 mRNA expression was higher in
the hypothyroid cochlea compared euthyroid. Additionally, the hypothyroid cochlea shows
a delay in the remodeling events of the cochlea as shown by the absence of a defined
tectorial membrane, a smaller opening of the inner sulcus and the prevalence of GER cells
(Fig 10A).
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Quantification of Dio3 mRNA in euthyroid and hypothyroid cochlea
qRT-PCR demonstrated that the expression of Dio3 mRNA levels in the euthyroid cochlea
were generally stable with a slight peak around P5. In the hypothyroid cochlea, levels were
also stable with a dip at P5 (Fig.11). Two-way ANOVA test indicated no effect of age or a
significant interaction for individually tested males and females. Additionally, no
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Figure 11. Dio3 mRNA expression during early postnatal development. (A) Control male
individuals had highest expression level at P5, with a slight decrease at P10 followed by
increasing at P15. (n=4-6) Hypothyroid male individuals had lower Dio3 expression at all ages
with the highest level at P10. (B) Control female individuals had highest expression level at P5,
with a slight decrease at P10 followed by increasing at P15. (n=3-6) Hypothyroid female
individuals had lower Dio3 expression at all ages with the highest level at P10. (C) Control
individuals had highest expression level at P5, with a decrease at P10 followed by increasing at
P15. (n=6 male and female, per age, per treatment). Hypothyroid individuals had lower Dio3
expression at all ages with the highest level at P10. Comparison of both groups found
significantly higher Dio3 mRNA expression in control pups at P5 (*p=0.0171).
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differences were detected between male and female pups within pups of the same age and
treatment group. For simplicity, male and female data was pooled since the data show the
same general trend whether sexes were pooled or separate.
Two-way ANOVA test indicated no effect of age or a significant interaction for the
combined analysis. However, there was an effect on treatment (F (1,70) =7.828, p<0.0066**)
when both sexes were combined. Overall, Dio3 mRNA levels were lower in hypothyroid
cochlea compared to euthyroid cochlea. Post hoc analysis reported at P5 that Dio2
expression was significantly lower in hypothyroid pups compared to the euthyroid controls
(Fig. 11C).
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Discussion
This study was conducted to investigate the expression of deiodinase enzymes in
the developing cochlea when normal thyroid hormone levels are disrupted. Thyroid
hormone must be available during critical developmental windows prior to the onset of
auditory function because at later stages auditory deficits cannot be reversed by thyroid
hormone supplementation (Ng et al. 2004). We aimed to evaluate whether deiodinase
enzymes, D2 and D3, respond to perturbations in TH levels in a manner that is consistent
with a compensatory mechanism capable restoring TH action in cochlear tissue. Such a
response may protect the developing tissue from malformation under mild-moderate
hypothyroid conditions. Our results are partially inconsistent with this idea and suggest
that developmental programs that control deiodinase expression in development may be
dominant over adaptive mechanisms that are thought to respond to perturbations in serum
TH levels.

Compensation as a rescue mechanism
Considering the importance of thyroid hormone for normal development, there is
the assumption that developing tissues hold potent compensatory mechanisms that serve to
protect against small to moderate changes in circulation TH ( Sharlin et al. 2010). This idea
comes from the observation that T4 is secreted at a 10-times bigger volume than T3
(Graham et al. 2011), which indicates deiodinases must be present to regulate the tissuelevel availability of active TH.
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In fact, the deiodinases contribute to around 60% of all circulating T3 in rodents
and 80% in humans suggesting that an interference to the expression of these enzymes will
result in major problems with the serum T3 homeostasis (Abdalla and Bianco 2014).
Therefore, considering that these enzymes are developmentally regulated, any alteration or
delay in deiodinase expression may prevent these enzymes from not only functioning
normally to promote tissue development, but may also prevent the deiodinases from
working as adaptive mechanisms aimed at compensation.

Deiodinase II role in compensation
In the brain, D2 is proposed to function as a protective mechanism against
hypothyroidism due to observed increases in enzymatic activity and mRNA levels in
response to low T4 conditions (Giadano-Ferraz et al. 1999). Particularly in neural systems,
this protective system seems to be operating more efficiently due to their critical need for
TH. Similarly, it has been reported that the post-natal cochlea has important T3 demands
given that specific cochlear developmental events such as the formation of the tectorial
membrane, opening of the inner sulcus, and maturation of sensory epithelium require
temporal TH action (Deol 1973; Rusch et al. 2001; Ng et al. 2004). Therefore, D2 may
serve to protect these TH-dependent events of the cochlea against fluctuations in TH levels
that occur in hypothyroidism.
Ng et al. (2004) observed cochlear malformations upon deletion of D2 gene.
Inactivation of D2 resulted in delayed differentiation of known TH sensitive developmental
events including opening of the inner sulcus and malformation of the tectorial membrane.
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These malformations were also observed in our in-situ hybridization (Fig. 10).
Interestingly, these defects occur in tissues that not express D2 (Campos-Barros et al.
2002). This observation suggests that proper expression of D2 in these surrounding tissues
is necessary for proper cochlear development and auditory function (Ng et al. 2004).
Our quantification studies demonstrate that the post-natal surge in dio2 mRNA
expression is delayed in the hypothyroid cochlea. Importantly, at post-natal day 5 the level
of mRNA expression of dio2 is significantly lower than the control (Fig. 9C). This suggests
that even if sufficient T4 was reaching the tissue to prevent malformation, the system is
unable to utilize it due to its inability to activate it. Therefore, in the mouse cochlea, D2
cannot act as a compensatory mechanism until post-natal day P10 where dio2 mRNA levels
surpass the control. At this point, the tissue malformation will persist because even with
super physiological doses of T3 there are no significant changes to the morphology of the
tissue (Ng et al. 2004). Sharlin et al (2010), reported dio2 mRNA levels in the brain were
elevated in the hippocampus of P14 pups with 82 % reduction in total T4 serum. Our
findings show dio2 mRNA expression was significantly higher than the control the cochlea
at post-natal day 15 (Fig.9). This observation suggests that as development proceeds, D2
mRNA expression may eventually be sufficient to respond in a manner consistent with
compensation.

Deiodinase III role in compensation
Type 3 deiodinase enzyme functions to deplete active sources of thyroid hormone.
With that, it has been proposed to play a protective role in auditory development by
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preventing premature TH action in the developing cochlea. Studies in D3 knockout mice
showed that D3 activity is imperative for normal development of the cochlea. In the
absence of D3, an acceleration of cochlear development was observed that could be
phenocopied by providing provisions of excess T3. This observation indicated that in the
absence of D3, the cochlea is prematurely exposure to T3 which ultimately will lead to
malformation of cochlea and deafness (Ng et al. 2009).
We hypothesized that normal early postnatal decrease in D3 mRNA expression
would be delayed. Contrary to our hypothesis, we observed that hypothyroidism induced a
general reduction of D3 mRNA levels in the developing cochlea. Particularly, at postnatal
day 5, D3 mRNA levels were found to be significantly reduced in the hypothyroid cochlea
compared to the euthyroid cochlea. This was also the age where we observed a peak in D3
mRNA in the control group (Fig. 11). Interestingly, Ng et al. (2009) reported D3 levels to
be low postnatally with no transient postnatal peak similar to the present study.
Nonetheless, this report argued that the elevated Dio3 prenatally restricts TH action by
reducing TH availability. Although it is not immediately why our study observed postnatal
peak in Dio3 mRNA and the previous study did not, it might be due to differences in assay
sensitivity. The present study utilized highly sensitive qRT-PCR where the previous study
utilized northern blot. Additionally, the experimental ages between studies do not perfectly
match-up. Therefore, our observed bump in expression at P5 may have been missed
previously. Nonetheless, the persistent reduction in Dio3 mRNA levels observed in the
hypothyroid cochlea is indicative of an adaptive response that could be attempting to
compensate for the goitrogen-induced reductions in T4. Taken together, it appears as
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though Dio2 and Dio3 regulation during cochlear development as well as their ability to
respond in a predicted manner according to the compensation hypothesis are differentially
regulated.

Future studies
From the above information it can be concluded that development of the cochlea
and normal auditory function requires a tightly controlled and temporally regulated
availability of T3. This is achieved by synchronized and developmentally inverted
expression of D2 and D3 (Williams and Bassett 2011; Ng et al. 2013; Sharlin et al. 2010).
However, it is still unknown what is mediating this switch in expression of D2 and D3
during development of the cochlea.

Histone modifications
A plausible next step is investigating whether modifications to histones, such as
methylation and acetylation, are the underlying mechanism to the switch in D2 and D3
expression. Ambrosio et al reported in 2013 that LSD-1, a lysine-specific histone
demethylase, is essential for transcriptional induction of D2 and repression of D3 during
myogenesis. Interestingly, they reported that demethylation of H3-K9 on the Dio2
promoter might be the molecular mechanism underlying an increase in D2 expression that
is observed during the start of myogenesis (Ambrosio et al. 2013). It would be interesting
to investigate whether this holds true for the deiodinase expression in the developing
cochlea. We hypothesize that in hypothyroid mice, methylation of H3-K9 on the D2

39

promoter will remain high longer than euthyroid mice, mirroring the delay in D2 mRNA
observed in our studies, preventing the proper remodeling of auditory structures, and
ultimately hearing dysfunction. Changes in activating histone acetylation marks would be
expected to accompany the changes in methylation.
With regard to D3, an opposite pattern to that of D2 would be expected with low
D3 promoter histone methylation during the prenatal period and higher levels of
methylation postnatally.

Considering that D3 mRNA levels responded to goitrogen

treatment in manner that would be expected for compensatory mechanism (in contrast to
D2), it would be interesting to determine whether histone modifications are altered in a
developmentally hypothyroid state.
Enzyme activity
Measuring mRNA expression is not the same as measuring enzymatic activity.
Previous studies have demonstrated that in the developing euthyroid cochlea mRNA
expression tends to peak before the enzyme activity (Ng et al. 2009). Additionally, Sharlin
et al (2010) found that D2 activity in the brain was also elevated as a result low TH
conditions and concluded that D2 cannot fully protect the developing brain from a
reduction in TH action (Sharlin et al. 2010). Therefore, it will be important to measure
enzyme activity and determine how cochlear enzymatic activity responds to a low TH state.
It would not be surprising if activity changes were observed; supporting the idea that D2
has a role in acting as a compensatory mechanism in development.
Interestingly, the D2 and D3 pathway, and thus the tissue-specific TH signaling is
regulated by ubiquination (Sagar et al. 2007; Bianco and Conceição, 2018). Ubiquination
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is a critical, post-translational regulator of protein stability. It is also able to regulate
enzyme activity by transiently inactivating enzyme function through conformational
changes which can be reversed upon deubiquination (De Castro et al. 2015; Sagar et al.
2007; Gereben et al. 2000). In the chicken developing growth plate, Hedgehog signaling
inhibits D2 mediated T3 production by inducing WSB-1, a ubiquitin ligase that targets D2
dimers. Interestingly, at the same time, hedgehog signaling stimulates D3 expression.
(Dentice et al. 2005; Sagar et al. 2007). Sagar et al (2007) reported that ubiquination is able
to inactivate D2 enzyme by transiently interfering with its dimeric conformation.
Additionally, they reported the ability of VDU-1 based catalytic core complexes to trigger
the removal of this initial ubiquination to favor a model where dimeric D2 is deubiquinated rather than being assembled every time (Sagar et al. 2007). This suggested
model represents a physiological advantage that might provide a moderate compensation
effects in developing tissues such as the cochlea. Under the assumption that ubiquinated
enzymes might be able to respond faster to changes in TH availability than mRNA because
of the de-ubiquination reaction requires less than transcription and translation.
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